NCT03727724已完成2 期
Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 4
- 主要终点
- Disease control rate after 18 weeks
研究概览
简要总结
This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically or cytologically confirmed stage IV non-small cell lung cancer, harboring an EGFR exon 20 insertion mutation.
- •18 years or older at time of study entry.
- •Life expectancy of at least three months.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix 1).
- •Measurable disease, according to RECIST 1.
- •At baseline adequate fresh or archived tissue from a histological biopsy or a cellblock obtained by fine needle aspiration of a tumor lesion that is not radiated prior to biopsy, must be available. Baseline tissue samples must have been obtained after the last line of systemic therapy prior to study entry.
- •Adequate normal organ and marrow function as defined below:
- •Absolute leukocyte count ≥ 3 x 109/L (> 3000 per mm3)
- •Platelet count ≥ 75 x 109/L (>75,000 per mm3)
- •Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤ 5x upper limit of normal (ULN).
- •Serum creatinine clearance >30 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance.
- •Women of child-bearing potential: these subjects must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use highly effective contraception, as defined in section 5.2.2, from 7 days prior to enrollment, throughout the treatment period and for seven months after completion of the treatment with cetuximab.
- •Males must agree to take appropriate precautions to avoid fathering a child from the first dose of study treatment through 3 months after the final administration of investigational drugs.
- •Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Ability to give written informed consent before patient registration.
排除标准
- •Participation in another clinical study with an investigational product during the last 2 weeks.
- •Prior treatment with EGFR targeting antibodies (prior treatment with EGFR TKI's is allowed).
- •Other active malignancy.
- •History of hypersensitivity to afatinib or cetuximab.
- •Major surgery (excluding diagnostic procedures e.g. mediastinoscopy or video assisted thoracic surgery (VATS) biopsy) within 28 days of the start of study treatment.
- •Radiotherapy less than two weeks prior to the start of study treatment.
- •Symptomatic brain metastases.
- •Breast feeding is not allowed during study treatment.
- •Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, myocardial infarction within 12 months prior to the study entry, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety and anti-tumor activity of the test drugs.
研究组 & 干预措施
Afatinib plus cetuximab
Experimental
Afatinib, 40 mg once daily, orally.
Cetuximab, 500 mg/m² intravenously, every 2 weeks.
Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs.
干预措施: Afatinib (Drug)
Afatinib plus cetuximab
Experimental
Afatinib, 40 mg once daily, orally.
Cetuximab, 500 mg/m² intravenously, every 2 weeks.
Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs.
干预措施: Cetuximab (Drug)
结局指标
主要结局
Disease control rate after 18 weeks
时间窗: 18 weeks
To determine the disease control rate at 18 weeks of afatinib and cetuximab treatment in patients with NSCLC harboring an EGFR exon 20 insertion mutation.
次要结局
- Objective tumor response(Scans every 6 weeks until tumor progression, start of another treatment or death.)
- Safety (intensity and incidence of adverse events)(Up to 30 days after last study drug intake.)
- Duration of response (DOR)(Scans every 6 weeks until tumor progression)
- Progression free survival(Until progression, every 6 weeks up to progression)
- Overall survival(Every 6 weeks up to death)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
1 期
Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerGastrointestinal NeoplasmsPancreatic NeoplasmsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsNCT02450656The Netherlands Cancer Institute320
进行中（未招募）
1 期
Afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancerEGFR exon 20 insertion positive non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001521-97-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis37
已完成
2 期
Phase II single arm study of afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancer10038666non-small cell lung cancerlung cancerNL-OMON55757Antoni van Leeuwenhoek Ziekenhuis37
已完成
2 期
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast CancerBreast NeoplasmsNCT01325428Boehringer Ingelheim26
招募中
2 期
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLCCarcinoma, Non-Small-Cell LungNCT06709859Shandong Public Health Clinical Center30